NCT06191991View on ClinicalTrials.gov

A Phase 1 Study to Evaluate the Drug-Drug Interaction Potential Between ALG-055009 and Statin Therapy(Ies)

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

November 3, 2023

Primary Completion Date

November 27, 2023

Study Completion Date

December 4, 2023

Conditions
Healthy Volunteers
Interventions
DRUG

Atorvastatin

40 mg

DRUG

ALG-055009

0.9 mg

DRUG

Rosuvastatin

10 mg

Trial Locations (1)

78744

PPD Austin Research Unit, Austin

Sponsors
All Listed Sponsors
lead

Aligos Therapeutics

INDUSTRY

NCT06191991 - A Phase 1 Study to Evaluate the Drug-Drug Interaction Potential Between ALG-055009 and Statin Therapy(Ies) | Biotech Hunter | Biotech Hunter